Fabrazyme 35 MG vials
Ended Awarded Last action
- Contract number
- SPE2DR26FFBT8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $35,277
Award facts
- Contract value 100% obligated
- $35,276.70 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $35,276.70 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Fabrazyme 35 mg vials. The award was issued on January 2, 2026, with an ultimate completion date of January 26, 2026, and carries no set-aside designation, indicating the vendor competed in an unrestricted procurement environment. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy that establishes multiple regional prime vendor contractors to supply pharmaceutical products to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has demonstrated substantial capability as a critical supplier within the federal pharmaceutical supply chain, with its IDC featuring a $499.999 billion ceiling value and an ultimate completion date of December 31, 2036. The contract encompasses a 30-month base period with three 30-month option periods and authorizes the issuance of firm fixed-price delivery orders for an extensive range of pharmaceuticals including branded and generic prescription drugs, over-the-counter medications, biologics, vaccines, and medical consumables. The company's established performance on numerous prior delivery orders across diverse therapeutic categories positions it to effectively fulfill the specialized pharmaceutical requirements of the Department of Defense's global military medical system.
Quick answers
Who was awarded contract SPE2DR26FFBT8?
SPE2DR26FFBT8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 2, 2026.
How much is contract SPE2DR26FFBT8 worth?
The government has obligated $35,277 on SPE2DR26FFBT8.
Is contract SPE2DR26FFBT8 an order under another contract?
Yes. SPE2DR26FFBT8 is a delivery order under SPE2DR25D9239, an indefinite delivery contract.
Was contract SPE2DR26FFBT8 competed?
The extent of competition for SPE2DR26FFBT8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award